Revvity (NYSE:RVTY) Updates FY 2025 Earnings Guidance

Revvity (NYSE:RVTY) updated its FY 2025 earnings guidance on Monday. The company provided EPS guidance of 4.900-5.000 for the period, compared to the consensus EPS estimate of 4.940. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Raymond James restated an “outperform” rating and set a $145.00 price objective (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Sanford C. Bernstein lowered Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price target for the company. in a report on Friday, January 10th. Wells Fargo & Company decreased their target price on Revvity from $130.00 to $102.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Robert W. Baird dropped their price target on Revvity from $141.00 to $127.00 and set an “outperform” rating on the stock in a research report on Monday, April 21st. Finally, KeyCorp boosted their price target on Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $130.50.

Revvity Trading Up 0.8 %

RVTY opened at $95.00 on Tuesday. Revvity has a 1-year low of $88.53 and a 1-year high of $129.50. The company has a market cap of $11.41 billion, a P/E ratio of 42.99, a PEG ratio of 3.82 and a beta of 1.07. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The company’s 50 day moving average is $104.47 and its 200-day moving average is $112.80.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.05. The firm had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the company posted $0.98 EPS. Equities research analysts predict that Revvity will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend is Friday, July 18th. Revvity’s dividend payout ratio is presently 12.67%.

Insider Activity

In related news, insider Joel S. Goldberg sold 15,170 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the transaction, the insider now directly owns 33,400 shares in the company, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.68% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.